| Medical and Health Sciences | 2021-2025 | 198 | US 74 | 99.96 |
| Hematology | Lifetime | 26 | US 20 | 99.84 |
| Molecular Biology | Lifetime | 758 | US 461 | 99.61 |
| Oncology | Lifetime | 614 | US 338 | 98.80 |
| Public, Environmental and Occupational Health | Lifetime | 965 | US 493 | 98.61 |
| Medical Genetics | Lifetime | 213 | US 108 | 98.40 |
| Cancer Research | Lifetime | 616 | US 326 | 95.82 |
| Dermatology | Lifetime | 810 | US 330 | 90.65 |
| Hematology | 2021-2025 | 6 | US 5 | 99.91 |
| Molecular Biology | 2021-2025 | 215 | US 59 | 99.06 |
| Medical Genetics | 2021-2025 | 78 | US 31 | 97.61 |
| Public, Environmental and Occupational Health | 2021-2025 | 327 | US 118 | 97.18 |
| Oncology | 2021-2025 | 330 | US 138 | 96.74 |
| Immunology | 2021-2025 | 406 | US 151 | 88.64 |
| Dermatology | 2021-2025 | 291 | US 102 | 84.75 |
| Acute Myeloid Leukemia Research | Lifetime | 14 | US 12 | 99.93 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 20 | US 16 | 99.82 |
| Histone Deacetylase Inhibitors Research | Lifetime | 16 | US 14 | 99.75 |
| Acute Lymphoblastic Leukemia research | Lifetime | 39 | US 32 | 99.74 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 83 | US 54 | 99.69 |
| Protein Degradation and Inhibitors | Lifetime | 53 | US 30 | 99.49 |
| Multiple Myeloma Research and Treatments | Lifetime | 84 | US 47 | 99.41 |
| Retinoids in leukemia and cellular processes | Lifetime | 61 | US 37 | 99.15 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 64 | US 33 | 99.38 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 265 | US 127 | 99.20 |
| Cell death mechanisms and regulation | Lifetime | 88 | US 38 | 99.18 |
| Immune cells in cancer | Lifetime | 171 | US 66 | 98.90 |
| CAR-T cell therapy research | Lifetime | 257 | US 157 | 99.16 |
| Hematopoietic Stem Cell Transplantation | Lifetime | 223 | US 127 | 99.01 |
| RNA Interference and Gene Delivery | Lifetime | 664 | US 270 | 98.31 |
| Chemokine receptors and signaling | Lifetime | 140 | US 62 | 97.55 |
| Cutaneous lymphoproliferative disorders research | Lifetime | 221 | US 98 | 97.65 |
| Cancer-related Molecular Pathways | Lifetime | 841 | US 431 | 97.30 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 565 | US 309 | 95.89 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 647 | US 316 | 95.13 |
| Eosinophilic Disorders and Syndromes | Lifetime | 649 | US 273 | 95.62 |
| Genomics, phytochemicals, and oxidative stress | Lifetime | 770 | US 261 | 94.29 |
| Phagocytosis and Immune Regulation | Lifetime | 475 | US 200 | 93.41 |
| Hematological disorders and diagnostics | Lifetime | 625 | US 291 | 92.72 |
| Neutropenia and Cancer Infections | Lifetime | 961 | US 402 | 92.91 |
| Acute Myeloid Leukemia Research | 2021-2025 | 7 | US 7 | 99.95 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 5 | US 5 | 99.81 |
| Acute Lymphoblastic Leukemia research | 2021-2025 | 12 | US 10 | 99.77 |
| Retinoids in leukemia and cellular processes | 2021-2025 | 2 | US 2 | 99.06 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 12 | US 11 | 99.74 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 22 | US 16 | 99.35 |
| Protein Degradation and Inhibitors | 2021-2025 | 32 | US 16 | 99.35 |
| CAR-T cell therapy research | 2021-2025 | 129 | US 72 | 99.08 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 92 | US 46 | 98.77 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 75 | US 34 | 98.97 |
| Phagocytosis and Immune Regulation | 2021-2025 | 44 | US 13 | 93.07 |
| Cutaneous lymphoproliferative disorders research | 2021-2025 | 66 | US 29 | 96.11 |
| Cell death mechanisms and regulation | 2021-2025 | 22 | US 4 | 93.09 |
| Hematopoietic Stem Cell Transplantation | 2021-2025 | 243 | US 120 | 95.76 |
| Neutropenia and Cancer Infections | 2021-2025 | 108 | US 48 | 92.38 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 704 | US 162 | 88.52 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 885 | US 358 | 92.74 |
| Hematological disorders and diagnostics | 2021-2025 | 281 | US 83 | 72.91 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 563 | US 83 | 65.83 |
